Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT02658032
Official study title

Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)

Study summary

The purpose of this study is to test the efficacy of two separate, sequential interventions to promote tobacco cessation/reduction in patients who are screened for lung cancer or are eligible for lung cancer screening. Each intervention will be compared to standard of care. The first intervention will be a personalized message intervention, the second intervention will consist of a biofeedback-based intervention.

Ask AI to explain this study
Start here

Key things to know

Main goalPrevention

This describes the study’s primary purpose.

What is being studiedpersonalized cessation care and bio feedback

Plus 1 other study approaches.

Who it may be forSmoking Cessation · Biofeedback

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 21, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Yale University

Study sponsor

01
Study overview

What this study is about

Purpose
Prevention
Study type
Interventional
Phase
Not applicable
Sponsor
Yale University
Interventions being studied
Behavioral: personalized cessation care; Behavioral: bio feedback; Other: standard care
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Supportive or behavioral care→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Current Smoker.
  • 20 pack per year smoking history.
  • Eligible for the Smilow treatment program.
  • Willing to enroll in smoking cessation program.
  • Willing to be randomized in smoking cessation study.
  • English speaking.
Reasons someone may not be able to joinExclusion criteria
  • Dementia or current serious psychiatric or unstable medical illness.
  • Pregnancy or breast feeding.
  • Known fat malabsorption diseases that may affect skin carotenoid status.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Yale UniversityNew Haven, Connecticut
  • Medical University of South Carolina: Hollings Cancer CenterCharleston, South Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 21, 2023. Always confirm current availability with the study team.

View original record ↗